Summary for 9O6H
| Entry DOI | 10.2210/pdb9o6h/pdb |
| Descriptor | Histone-arginine methyltransferase CARM1, 5'-S-(3-{[(4'-chloro[1,1'-biphenyl]-3-yl)methyl]amino}propyl)-5'-thioadenosine (3 entities in total) |
| Functional Keywords | prmt4, carm1, transferase |
| Biological source | Homo sapiens (human) |
| Total number of polymer chains | 4 |
| Total formula weight | 152944.73 |
| Authors | Bush, M.,Noinaj, N.,Huang, R.,Deng, Y. (deposition date: 2025-04-13, release date: 2026-05-13, Last modification date: 2026-05-27) |
| Primary citation | Kulkarni, A.S.,Deng, Y.,Nam, H.S.,Zhao, T.,Masal, D.P.,Bush, M.M.,Noinaj, N.,Huang, R. Tailoring PRMT Inhibition: Shifting PRMT7 Selectivity to PRMT4 through "T-Shape" Strategy and "Linker-Specific" Preferences. J.Med.Chem., 69:9977-9990, 2026 Cited by PubMed Abstract: Protein arginine methyltransferases (PRMTs) are appealing therapeutic targets due to their critical roles in regulating numerous cellular processes and their dysregulation in various diseases. Although SAH-based inhibitors effectively target PRMTs, achieving selectivity across different methyltransferases remains a significant challenge. Herein, we employed a hybrid strategy that incorporates optimal linker length and "T-shape" modifications to enhance inhibitor selectivity. Starting with a selective PRMT7 inhibitor SGC8158 (IC <2.5 nM), we successfully transformed it into a selective PRMT4 inhibitor AK442 (IC = 2.6 nM). This approach highlights the potential of these design strategies to tune inhibitor selectivity, facilitating the development of isoform-specific PRMT inhibitors from existing scaffolds. PubMed: 42066234DOI: 10.1021/acs.jmedchem.5c01782 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (1.97 Å) |
Structure validation
Download full validation report






